deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00582816

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Reduced Intensity Haploidentical Transplantation With NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, BMT06407

Sponsor: Miltenyi Biomedicine GmbH

Conditions Leukemia Solid Tumors
Interventions Clinimacs Cell Separation System DLI conditioning chemotherapy
Updated 11 times since 2017 Last updated: Nov 19, 2019 Started: Aug 31, 2008 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

toxicity

Other Leukemia trials with similar outcome

Browse all Leukemia trials

This PHASE1/PHASE2 trial investigates Leukemia and Solid Tumors and is currently terminated or withdrawn. Miltenyi Biomedicine GmbH leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotTerminated~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2020 · 19 months · monthly snapshotTerminated~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshotTerminated~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshotTerminated~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 21 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Feb 2020 — Aug 2020 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2020 — Feb 2020 [monthly]

    Terminated PHASE1_PHASE2

  3. Jun 2018 — Jan 2020 [monthly]

    Terminated PHASE1_PHASE2

  4. Aug 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  5. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Miltenyi Biomedicine GmbH
  • University of Wisconsin, Madison
Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations